首页 > 最新文献

Nephrologie & therapeutique最新文献

英文 中文
Withholding or withdrawing life support in nephrology: a perspective in the French-speaking background 肾脏病学中暂停或撤消生命支持:法语背景下的视角
Pub Date : 2024-06-26 DOI: 10.1684/ndt.2024.81

Chronic kidney disease (CKD) characterized by long duration, simplicity at beginning versus complexity at advanced stages. Hemodialysis and peritoneal dialysis are renal replacement therapy allowing life extension, but comorbidities and frailty could be burdensome over time. The academic society, Société Francophone de Néphrologie, Dialyse, Transplantation (SFNDT), publishes clinical practice guidelines to optimize CKD treatment in this context, to support shared decision-making in the appropriate initiation of and withdrawal from dialysis, and to supervise end-of-life cares in the French-speaking countries.

慢性肾脏病(CKD)的特点是病程长、初期简单而晚期复杂。血液透析和腹膜透析是肾脏替代疗法,可以延长患者的生命,但随着时间的推移,合并症和虚弱可能会成为患者的负担。法语国家肾脏病、透析和移植学会(SFNDT)发布了临床实践指南,以优化在这种情况下的 CKD 治疗,支持在适当开始和退出透析时共同决策,并监督法语国家的临终关怀。
{"title":"Withholding or withdrawing life support in nephrology: a perspective in the French-speaking background","authors":"","doi":"10.1684/ndt.2024.81","DOIUrl":"10.1684/ndt.2024.81","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) characterized by long duration, simplicity at beginning versus complexity at advanced stages. Hemodialysis and peritoneal dialysis are renal replacement therapy allowing life extension, but comorbidities and frailty could be burdensome over time. The academic society, Société Francophone de Néphrologie, Dialyse, Transplantation (SFNDT), publishes clinical practice guidelines to optimize CKD treatment in this context, to support shared decision-making in the appropriate initiation of and withdrawal from dialysis, and to supervise end-of-life cares in the French-speaking countries.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 3","pages":"1-34"},"PeriodicalIF":0.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of stages 3-5 chronic kidney disease in New Caledonia 新喀里多尼亚慢性肾病 3-5 期的发病率
Pub Date : 2024-06-26 DOI: 10.1684/ndt.2024.77
Noémie Baroux, Élodie Magnat, Marina Cauchy, Jean-François Cantin, Raphael Cohen, Pascale Domingue-Mena

New Caledonia is a French territory located in the South Pacific Ocean. The prevalence rate of end-stage renal disease is nearly 3,000 per million inhabitants, making it one of the highest prevalence rates in the world. Preventing chronic kidney disease is a major public health issue. This article presents prevalence rates of chronic kidney disease (CKD) stages 3-5 for New Caledonia defined by a glomerular filtration rate estimated below 60 mL/min/1.73 m2. Estimation was assessed from data collected during two “Adult health barometer” surveys carried out in the general adult population. Therefore, our study assessed two prevalence rates: 7.8% [6.1; 10.1] and 5.3% [3.3; 8.5]. Those prevalence rates were two to four times higher than in mainland France which is consistent with the high prevalence rate of end stage renal disease treated in New Caledonia. Hence, CKD prevention is essential for New Caledonia.

新喀里多尼亚是位于南太平洋的法国领土。新喀里多尼亚的终末期肾病发病率接近每百万居民 3,000 人,是世界上发病率最高的地区之一。预防慢性肾病是一个重大的公共卫生问题。本文介绍了新喀里多尼亚慢性肾脏病(CKD)3-5 期的患病率,其定义是肾小球滤过率低于 60 mL/min/1.73 m2。估计值是根据两次 "成人健康晴雨表 "调查中收集到的数据进行评估的。因此,我们的研究评估了两个患病率:分别为 7.8% [6.1; 10.1] 和 5.3% [3.3; 8.5]。这些患病率比法国本土高出 2 到 4 倍,这与新喀里多尼亚治疗终末期肾病的高患病率是一致的。因此,在新喀里多尼亚,预防慢性肾功能衰竭至关重要。
{"title":"Prevalence of stages 3-5 chronic kidney disease in New Caledonia","authors":"Noémie Baroux, Élodie Magnat, Marina Cauchy, Jean-François Cantin, Raphael Cohen, Pascale Domingue-Mena","doi":"10.1684/ndt.2024.77","DOIUrl":"10.1684/ndt.2024.77","url":null,"abstract":"<p><p>New Caledonia is a French territory located in the South Pacific Ocean. The prevalence rate of end-stage renal disease is nearly 3,000 per million inhabitants, making it one of the highest prevalence rates in the world. Preventing chronic kidney disease is a major public health issue. This article presents prevalence rates of chronic kidney disease (CKD) stages 3-5 for New Caledonia defined by a glomerular filtration rate estimated below 60 mL/min/1.73 m2. Estimation was assessed from data collected during two “Adult health barometer” surveys carried out in the general adult population. Therefore, our study assessed two prevalence rates: 7.8% [6.1; 10.1] and 5.3% [3.3; 8.5]. Those prevalence rates were two to four times higher than in mainland France which is consistent with the high prevalence rate of end stage renal disease treated in New Caledonia. Hence, CKD prevention is essential for New Caledonia.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 3","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nurse-assisted arterio-venous fistula cannulation during home hemodialysis: first results of the DIADIDEAL study 家庭血液透析期间护士协助动静脉瘘插管:DIADIDEAL 研究的初步结果
Pub Date : 2024-06-19 DOI: 10.1684/ndt.2024.82
Laurence Pautret, Anne-Céline Galle, Anne Radiguet, Catherine Thibault, Ludivine Videloup, Sonia Guillouët, Thierry Lobbedez, Patrick Henri, Maxence Ficheux, Clémence Béchade

Introduction: We have launched a pilot study, called DIADIDEAL, to propose nurse-assistance at home for arterio-venous fistula (AVF) cannulation in home hemodialysis (HHD) patients. The aim of the present study was to describe enrollment of the patients and their nurses.

Materials: All prevalent HD patients on 30th November 2018 with no medical contraindication to HDD treatment and all incident patients on dialysis from the 30th November 2018 to the 21st April 2023 were eligible.

Results: Among 155 prevalent HD patients, 4 patients were included. Among the 276 incident patients on dialysis during the study period, 6 were included. We have phoned 23 nurse centers during the recruitment period. Eight of them agreed to learn in our unit how to cannulate AVF; 27 private nurses were enrolled.

Discussion: The results of the DIADIDEAL study will be available in 2024; we hope it will lead to a reimbursement of nurse-AVF cannulation at home in HDD.

导言:我们发起了一项名为 "DIADIDEAL "的试验性研究,建议护士协助家庭血液透析(HHD)患者在家中进行动静脉瘘(AVF)插管。本研究旨在描述患者及其护士的注册情况:2018年11月30日所有流行的HHD患者,且无HDD治疗的医学禁忌症,以及2018年11月30日至2023年4月21日所有透析的事件患者均符合条件:在155名流行的HD患者中,有4名患者被纳入。在研究期间进行透析的 276 名事件患者中,有 6 名患者被纳入。在招募期间,我们给 23 个护士中心打了电话。讨论:讨论:DIADIDEAL 研究结果将于 2024 年公布;我们希望该研究能为 HDD 患者在家中进行护士动静脉瓣膜置管提供报销。
{"title":"Nurse-assisted arterio-venous fistula cannulation during home hemodialysis: first results of the DIADIDEAL study","authors":"Laurence Pautret, Anne-Céline Galle, Anne Radiguet, Catherine Thibault, Ludivine Videloup, Sonia Guillouët, Thierry Lobbedez, Patrick Henri, Maxence Ficheux, Clémence Béchade","doi":"10.1684/ndt.2024.82","DOIUrl":"10.1684/ndt.2024.82","url":null,"abstract":"<p><strong>Introduction: </strong>We have launched a pilot study, called DIADIDEAL, to propose nurse-assistance at home for arterio-venous fistula (AVF) cannulation in home hemodialysis (HHD) patients. The aim of the present study was to describe enrollment of the patients and their nurses.</p><p><strong>Materials: </strong>All prevalent HD patients on 30th November 2018 with no medical contraindication to HDD treatment and all incident patients on dialysis from the 30th November 2018 to the 21st April 2023 were eligible.</p><p><strong>Results: </strong>Among 155 prevalent HD patients, 4 patients were included. Among the 276 incident patients on dialysis during the study period, 6 were included. We have phoned 23 nurse centers during the recruitment period. Eight of them agreed to learn in our unit how to cannulate AVF; 27 private nurses were enrolled.</p><p><strong>Discussion: </strong>The results of the DIADIDEAL study will be available in 2024; we hope it will lead to a reimbursement of nurse-AVF cannulation at home in HDD.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 3","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Withholding or withdrawing life support in nephrology: a perspective in the French-speaking background 肾脏病学中暂停或撤消生命支持:法语背景下的视角
Pub Date : 2024-06-19 DOI: 10.1684/ndt.2024.81
L Frimat

Chronic kidney disease (CKD) characterized by long duration, simplicity at beginning versus complexity at advanced stages. Hemodialysis and peritoneal dialysis are renal replacement therapy allowing life extension, but comorbidities and frailty could be burdensome over time. The academic society, Société Francophone de Néphrologie, Dialyse, Transplantation (SFNDT), publishes clinical practice guidelines to optimize CKD treatment in this context, to support shared decision-making in the appropriate initiation of and withdrawal from dialysis, and to supervise end-of-life cares in the French-speaking countries.

慢性肾脏病(CKD)的特点是病程长、初期简单而晚期复杂。血液透析和腹膜透析是肾脏替代疗法,可以延长患者的生命,但随着时间的推移,合并症和体弱会给患者带来沉重的负担。法语国家肾脏病、透析和移植学会(SFNDT)发布了临床实践指南,以优化在这种情况下的 CKD 治疗,支持在适当开始和退出透析时共同决策,并监督法语国家的临终关怀。
{"title":"Withholding or withdrawing life support in nephrology: a perspective in the French-speaking background","authors":"L Frimat","doi":"10.1684/ndt.2024.81","DOIUrl":"10.1684/ndt.2024.81","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) characterized by long duration, simplicity at beginning versus complexity at advanced stages. Hemodialysis and peritoneal dialysis are renal replacement therapy allowing life extension, but comorbidities and frailty could be burdensome over time. The academic society, Société Francophone de Néphrologie, Dialyse, Transplantation (SFNDT), publishes clinical practice guidelines to optimize CKD treatment in this context, to support shared decision-making in the appropriate initiation of and withdrawal from dialysis, and to supervise end-of-life cares in the French-speaking countries.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 3","pages":"1-34"},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Difelikefalin and treatment of severe pruritus associated with chronic kidney disease - Real-life retrospective study in a dialysis center 地匹福林与慢性肾病相关严重瘙痒症的治疗--透析中心的真实回顾性研究
Pub Date : 2024-06-14 DOI: 10.1684/ndt.2024.78
Rémi Brasme, Claire Cartery, Marlène Goubet, Marie-Flore Hennino, Nathalie Maisonneuve

Introduction: Difelikefalin is to date the first and only specific treatment to be approved for the treatment of moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) in adult patients on hemodialysis.

Patients and methods: This was a retrospective, single-center, real-life study in hemodialysis patients with CKD-aP treated with difelikefalin. The primary objective was to evaluate the evolution of the intensity of pruritus during treatment with difelikefalin using the Worst Itch Intensity-Numerical Rating Scale (WI-NRS). Adult patients were included if they had been on hemodialysis for at least 3 months and were suffering from moderate to severe CKD-aP (objectified by the WI-NRS score) for which difelikefalin had been prescribed.

Results: 11 patients (7 men and 4 women; mean age, 63.8 years) with a mean (SD) weekly dialysis time of 13 h (2.4) were included. The mean hemodialysis duration was 5 (3.6) years and the mean pruritus duration was 4.3 (3.2) years. At inclusion, on-going treatments of CKD-aP were emollients in all patients and antihistamines in 9 patients. The mean WI-NRS score was 7.4 (1.1) at initiation of difelikefalin. At last assessment after a median follow-up of 9.0 months, the mean change of WI-NRS score was -5.1 (2.9) and 82% of patients had a decrease ≥ 3 points. Mild to moderate adverse reactions to difelikefalin were reported in 4 patients, all of whom recovered without sequelae.

Conclusion: These results show that difelikefalin, prescribed according to its therapeutic indication, is effective in the treatment of CKD-aP under real-life conditions, outside the controlled conditions of a clinical trial.

简介地匹福林是迄今为止第一种也是唯一一种获准用于治疗成年血液透析患者中重度慢性肾病相关性瘙痒症(CKD-aP)的特效药物:这是一项回顾性、单中心、真实生活研究,研究对象是接受地匹法林治疗的慢性肾脏病相关性瘙痒症(CKD-aP)血液透析患者。研究的主要目的是使用最严重瘙痒强度数字评定量表(WI-NRS)评估地匹福林治疗期间瘙痒强度的变化情况。纳入的成年患者必须至少接受过 3 个月的血液透析,并患有中度至重度 CKD-aP(以 WI-NRS 评分为指标),且处方为地非司酮:共纳入 11 名患者(7 名男性,4 名女性;平均年龄 63.8 岁),平均(标清)每周透析时间为 13 小时(2.4)。平均血液透析时间为 5 (3.6) 年,平均瘙痒持续时间为 4.3 (3.2) 年。纳入时,所有患者正在接受的 CKD-aP 治疗均为润肤剂治疗,9 名患者接受了抗组胺剂治疗。开始使用地匹福林时,平均 WI-NRS 评分为 7.4(1.1)分。在中位随访9.0个月后的最后一次评估中,WI-NRS评分的平均变化为-5.1(2.9)分,82%的患者评分下降≥3分。据报道,4名患者出现了轻度至中度的地非司酮不良反应,但他们均已康复,没有留下后遗症:这些结果表明,在临床试验的受控条件之外,根据其治疗适应症处方的地非司酮在实际生活条件下治疗 CKD-aP 是有效的。
{"title":"Difelikefalin and treatment of severe pruritus associated with chronic kidney disease - Real-life retrospective study in a dialysis center","authors":"Rémi Brasme, Claire Cartery, Marlène Goubet, Marie-Flore Hennino, Nathalie Maisonneuve","doi":"10.1684/ndt.2024.78","DOIUrl":"https://doi.org/10.1684/ndt.2024.78","url":null,"abstract":"<p><strong>Introduction: </strong>Difelikefalin is to date the first and only specific treatment to be approved for the treatment of moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) in adult patients on hemodialysis.</p><p><strong>Patients and methods: </strong>This was a retrospective, single-center, real-life study in hemodialysis patients with CKD-aP treated with difelikefalin. The primary objective was to evaluate the evolution of the intensity of pruritus during treatment with difelikefalin using the Worst Itch Intensity-Numerical Rating Scale (WI-NRS). Adult patients were included if they had been on hemodialysis for at least 3 months and were suffering from moderate to severe CKD-aP (objectified by the WI-NRS score) for which difelikefalin had been prescribed.</p><p><strong>Results: </strong>11 patients (7 men and 4 women; mean age, 63.8 years) with a mean (SD) weekly dialysis time of 13 h (2.4) were included. The mean hemodialysis duration was 5 (3.6) years and the mean pruritus duration was 4.3 (3.2) years. At inclusion, on-going treatments of CKD-aP were emollients in all patients and antihistamines in 9 patients. The mean WI-NRS score was 7.4 (1.1) at initiation of difelikefalin. At last assessment after a median follow-up of 9.0 months, the mean change of WI-NRS score was -5.1 (2.9) and 82% of patients had a decrease ≥ 3 points. Mild to moderate adverse reactions to difelikefalin were reported in 4 patients, all of whom recovered without sequelae.</p><p><strong>Conclusion: </strong>These results show that difelikefalin, prescribed according to its therapeutic indication, is effective in the treatment of CKD-aP under real-life conditions, outside the controlled conditions of a clinical trial.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 3","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of immunosuppressive therapy after functional renal graft failure: Results of a practice survey of French-speaking nephrologists 功能性肾移植失败后的免疫抑制治疗管理:法语肾病专家实践调查结果
Pub Date : 2024-06-14 DOI: 10.1684/ndt.2024.79
Cyril Garrouste, Marine Freist, Mathilde Prezelin-Reydit, Antoine Bouquegneau, Thomas Fournier, Betoul Schvartz, Antoine Thierry, Virginie Paumier Sanson, Valentin Mayet, Bruno Pereira, Christophe Mariat

The management of patients with kidney transplant failure (KTF) remains a complex process involving multiple stakeholders. A working group of the Transplantation Commission of the French-speaking Society of Nephrology, Dialysis and Transplantation (SFNDT) conducted a survey on the management of immunosuppressants (IS) after KTF among nephrologists at transplant centres and general nephrologists in France, Switzerland and Belgium between March and June 2023.We analysed 232 replies from 58 nephrologists at transplant centres and 174 general nephrologists, aged 43.6 (+10.6) years. In the first three months following KTF, nephrologists reported discontinuing antimetabolite, calcineurin inhibitor (CNI) and corticosteroid treatment in 83%, 39.9% and 25.8% of cases respectively. Conversely, some nephrologists reported that they were continuing to use CNI (14%) and corticosteroids (19.1%) on a long-term basis. The patient’s comorbidities associated with the discontinuation of IS treatment are cancer and opportunistic infections as KT’s complications and presence of diabetes mellitus at KTF, whereas humoral rejection encourages the IS to be maintained. Transplantectomy is proposed by nephrologists most often for graft intolerance syndrome (86.5%), more rarely to discontinue IS (17.6%) or in the absence of plans of new transplantation (9.3%). In multivariate analyses, the presence of a protocol in the centre facilitated the management of IS by the general nephrologists.The management of IS after AFG by French-speaking nephrologists is heterogeneous. Specific prospective studies are needed to establish new best practice recommendations, based on more robust evidence, which could encourage better adherence by nephrologists.

肾移植失败(KTF)患者的管理仍然是一个复杂的过程,涉及多个利益相关方。法语区肾脏病学、透析和移植学会(SFNDT)移植委员会的一个工作组在2023年3月至6月期间对法国、瑞士和比利时的移植中心肾脏病学家和普通肾脏病学家进行了一次关于KTF后免疫抑制剂(IS)管理的调查。我们分析了来自58名移植中心肾脏病学家和174名普通肾脏病学家的232份答复,他们的年龄为43.6(+10.6)岁。在 KTF 术后的头三个月,肾病专家报告停止抗代谢药、降钙素抑制剂 (CNI) 和皮质类固醇治疗的比例分别为 83%、39.9% 和 25.8%。相反,一些肾病专家表示,他们仍在长期使用 CNI(14%)和皮质类固醇(19.1%)。与停止IS治疗相关的患者合并症有癌症和机会性感染(KT并发症),以及在KTF时存在糖尿病,而体液排斥反应则促使IS得以维持。肾脏病专家最常因移植物不耐受综合征(86.5%)而建议进行移植切除术,更少的情况是为了中止 IS(17.6%)或没有新的移植计划(9.3%)。在多变量分析中,中心内有协议有利于普通肾病专家对 IS 的管理。法语区肾病专家对AFG术后IS的处理方法各不相同,需要进行具体的前瞻性研究,以便根据更可靠的证据制定新的最佳实践建议,从而鼓励肾病专家更好地遵守这些建议。
{"title":"Management of immunosuppressive therapy after functional renal graft failure: Results of a practice survey of French-speaking nephrologists","authors":"Cyril Garrouste, Marine Freist, Mathilde Prezelin-Reydit, Antoine Bouquegneau, Thomas Fournier, Betoul Schvartz, Antoine Thierry, Virginie Paumier Sanson, Valentin Mayet, Bruno Pereira, Christophe Mariat","doi":"10.1684/ndt.2024.79","DOIUrl":"10.1684/ndt.2024.79","url":null,"abstract":"<p><p>The management of patients with kidney transplant failure (KTF) remains a complex process involving multiple stakeholders. A working group of the Transplantation Commission of the French-speaking Society of Nephrology, Dialysis and Transplantation (SFNDT) conducted a survey on the management of immunosuppressants (IS) after KTF among nephrologists at transplant centres and general nephrologists in France, Switzerland and Belgium between March and June 2023.\u0000We analysed 232 replies from 58 nephrologists at transplant centres and 174 general nephrologists, aged 43.6 (+10.6) years. In the first three months following KTF, nephrologists reported discontinuing antimetabolite, calcineurin inhibitor (CNI) and corticosteroid treatment in 83%, 39.9% and 25.8% of cases respectively. Conversely, some nephrologists reported that they were continuing to use CNI (14%) and corticosteroids (19.1%) on a long-term basis. The patient’s comorbidities associated with the discontinuation of IS treatment are cancer and opportunistic infections as KT’s complications and presence of diabetes mellitus at KTF, whereas humoral rejection encourages the IS to be maintained. Transplantectomy is proposed by nephrologists most often for graft intolerance syndrome (86.5%), more rarely to discontinue IS (17.6%) or in the absence of plans of new transplantation (9.3%). In multivariate analyses, the presence of a protocol in the centre facilitated the management of IS by the general nephrologists.\u0000The management of IS after AFG by French-speaking nephrologists is heterogeneous. Specific prospective studies are needed to establish new best practice recommendations, based on more robust evidence, which could encourage better adherence by nephrologists.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 3","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of stage 3-5 chronic kidney disease in New Caledonia 新喀里多尼亚慢性肾病 3-5 期的发病率。
Pub Date : 2024-06-13 DOI: 10.1684/ndt.2024.77
Noémie Baroux, Élodie Magnat, Marina Cauchy, Jean-François Cantin, Raphael Cohen, Pascale Domingue-Mena

New Caledonia is a French territory located in the South Pacific Ocean. The prevalence rate of end-stage renal disease is nearly 3,000 per million inhabitants, making it one of the highest prevalence rates in the world. Preventing chronic kidney disease is a major public health issue. This article presents prevalence rates of chronic kidney disease (CKD) stages 3-5 for New Caledonia defined by a glomerular filtration rate estimated below 60 mL/min/1.73 m2. Estimation was assessed from data collected during two “Adult health barometer” surveys carried out in the general adult population. Therefore, our study assessed two prevalence rates: 7.8% [6.1; 10.1] and 5.3% [3.3; 8.5]. Those prevalence rates were two to four times higher than in mainland France which is consistent with the high prevalence rate of end stage renal disease treated in New Caledonia. Hence, CKD prevention is essential for New Caledonia.

新喀里多尼亚是位于南太平洋的法国领土。新喀里多尼亚的终末期肾病发病率接近每百万居民 3,000 例,是世界上发病率最高的地区之一。预防慢性肾病是一个重大的公共卫生问题。本文介绍了新喀里多尼亚慢性肾脏病(CKD)3-5 期的患病率,其定义是肾小球滤过率低于 60 mL/min/1.73 m2。估计值是根据在普通成年人口中进行的两次 "成人健康晴雨表 "调查中收集的数据进行评估的。因此,我们的研究评估了两个患病率:分别为 7.8% [6.1; 10.1] 和 5.3% [3.3; 8.5]。这些患病率比法国本土高出 2 到 4 倍,这与新喀里多尼亚治疗终末期肾病的高患病率是一致的。因此,在新喀里多尼亚,预防慢性肾功能衰竭至关重要。
{"title":"Prevalence of stage 3-5 chronic kidney disease in New Caledonia","authors":"Noémie Baroux, Élodie Magnat, Marina Cauchy, Jean-François Cantin, Raphael Cohen, Pascale Domingue-Mena","doi":"10.1684/ndt.2024.77","DOIUrl":"10.1684/ndt.2024.77","url":null,"abstract":"<p><p>New Caledonia is a French territory located in the South Pacific Ocean. The prevalence rate of end-stage renal disease is nearly 3,000 per million inhabitants, making it one of the highest prevalence rates in the world. Preventing chronic kidney disease is a major public health issue. This article presents prevalence rates of chronic kidney disease (CKD) stages 3-5 for New Caledonia defined by a glomerular filtration rate estimated below 60 mL/min/1.73 m2. Estimation was assessed from data collected during two “Adult health barometer” surveys carried out in the general adult population. Therefore, our study assessed two prevalence rates: 7.8% [6.1; 10.1] and 5.3% [3.3; 8.5]. Those prevalence rates were two to four times higher than in mainland France which is consistent with the high prevalence rate of end stage renal disease treated in New Caledonia. Hence, CKD prevention is essential for New Caledonia.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 3","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mind the gap in kidney care: translating what we know into what we do. 关注肾脏护理中的差距:将我们的知识转化为我们的行动。
Pub Date : 2024-06-01 Epub Date: 2024-06-13 DOI: 10.1684/ndt.2024.80
Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu Fai Lui, Vassilios Liakopoulos, Alessandro Balducci

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.

从历史上看,新疗法从临床证据转化为日常实践平均需要 17 年的时间。鉴于目前已有的高效疗法可以预防或延缓肾病的发生和发展,这个时间太长了。现在是缩小我们所知道的与我们所做的之间差距的时候了。对于高血压和糖尿病等肾脏病常见风险因素的预防和管理,已有明确的指导方针,但全世界只有一小部分肾脏病患者被确诊,接受目标治疗的患者则更少。同样,绝大多数肾病患者都不知道自己的病情,因为肾病在早期往往是无声无息的。即使在已经确诊的患者中,许多人也没有接受适当的肾病治疗。考虑到肾病恶化、肾衰竭或死亡的严重后果,必须及早开始适当的治疗。必须从初级保健开始,最大限度地利用早期诊断和治疗肾病的机会。从患者到临床医生,从医疗系统到社会因素,存在着许多系统性障碍。为了维护和改善世界各地每个人的肾脏健康,必须认识到这些障碍中的每一个,以便制定和实施可持续的解决方案,不再拖延。
{"title":"Mind the gap in kidney care: translating what we know into what we do.","authors":"Valerie A Luyckx, Katherine R Tuttle, Dina Abdellatif, Ricardo Correa-Rotter, Winston W S Fung, Agnès Haris, Li-Li Hsiao, Makram Khalife, Latha A Kumaraswami, Fiona Loud, Vasundhara Raghavan, Stefanos Roumeliotis, Marianella Sierra, Ifeoma Ulasi, Bill Wang, Siu Fai Lui, Vassilios Liakopoulos, Alessandro Balducci","doi":"10.1684/ndt.2024.80","DOIUrl":"10.1684/ndt.2024.80","url":null,"abstract":"<p><p>Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 3","pages":"164-175"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with therapeutic non-adherence in renal transplant patients: a bicentric study in Algeria 肾移植患者不坚持治疗的相关因素:阿尔及利亚的一项双中心研究
Pub Date : 2024-05-15 Epub Date: 2024-04-04 DOI: 10.1684/ndt.2024.69
Akli Islem Chebli, Zeyneb Chelighem, Emad Shalabi, Younes Zebbiche, Nada Boubidi, Bahi Baraa, Nechoia Boumalha, Djihad Bouhlassa, Sara Abdennour

Introduction: Medication non-adherence is a global concern, particularly in the context of renal transplantation, where it leads to graft failures, increased hospitalizations, diminished quality of life for patients, and higher healthcare costs. The aim of this study was to assess the level of therapeutic adherence among Algerian kidney transplant recipients and identify potential influencing factors.

Methods: A descriptive, cross-sectional bicenter study was conducted among kidney transplant patients receiving outpatient care at two specialized medical centers in Algeria: the Urology Department of the Hospital Establishment for Urology, Nephrology, and Renal Transplantation in Constantine, and the Nephrology and Renal Transplantation Department of the University Hospital Center (CHU) in Blida, spanning from January to December 2022. Therapeutic adherence was assessed using the 8-item Morisky questionnaire, while the level of knowledge was analyzed through a 12-item questionnaire. Logistic regression was used to identify factors associated with non-adherence to therapy.

Results: This study included 130 patients with an average age of 47 years and a sex ratio of 1.7. The results revealed therapeutic non-adherence in 40.8% of the patients. Multivariate analysis identified several potentially associated factors, including residence, unemployment status, lack of affiliation with a health insurance fund, the use of a therapeutic regimen involving triple therapy, the occurrence of adverse effects, limited education level, and insufficient disease knowledge. Furthermore, non-adherence was associated with an increased risk of graft rejection.

Conclusion: The findings of this study highlight concerning therapeutic adherence among kidney transplant recipients, emphasizing the crucial importance of therapeutic education to improve treatment adherence and underscoring the need to integrate these factors into clinical patient management.

导言:不遵医嘱用药是一个全球关注的问题,尤其是在肾移植领域,它会导致移植失败、住院次数增加、患者生活质量下降以及医疗费用增加。本研究旨在评估阿尔及利亚肾移植受者的治疗依从性水平,并找出潜在的影响因素:这项描述性横断面双中心研究的对象是在阿尔及利亚两家专科医疗中心接受门诊治疗的肾移植患者,这两家医疗中心分别是君士坦丁市泌尿学、肾脏病学和肾移植医院的泌尿科和布利达市大学医院中心(CHU)的肾脏病学和肾移植科,研究时间跨度为 2022 年 1 月至 12 月。治疗依从性通过 8 项莫里斯基问卷进行评估,知识水平则通过 12 项问卷进行分析。采用逻辑回归法确定与不坚持治疗相关的因素:本研究共纳入 130 名患者,平均年龄 47 岁,男女比例为 1.7。结果显示,40.8%的患者不坚持治疗。多变量分析发现了几个潜在的相关因素,包括居住地、失业状况、未加入医疗保险基金、使用涉及三联疗法的治疗方案、出现不良反应、教育水平有限以及疾病知识不足。此外,不坚持治疗与移植排斥风险增加有关:本研究结果强调了肾移植受者治疗依从性的问题,强调了治疗教育对提高治疗依从性的重要性,并强调了将这些因素纳入临床患者管理的必要性。
{"title":"Factors associated with therapeutic non-adherence in renal transplant patients: a bicentric study in Algeria","authors":"Akli Islem Chebli, Zeyneb Chelighem, Emad Shalabi, Younes Zebbiche, Nada Boubidi, Bahi Baraa, Nechoia Boumalha, Djihad Bouhlassa, Sara Abdennour","doi":"10.1684/ndt.2024.69","DOIUrl":"10.1684/ndt.2024.69","url":null,"abstract":"<p><strong>Introduction: </strong>Medication non-adherence is a global concern, particularly in the context of renal transplantation, where it leads to graft failures, increased hospitalizations, diminished quality of life for patients, and higher healthcare costs. The aim of this study was to assess the level of therapeutic adherence among Algerian kidney transplant recipients and identify potential influencing factors.</p><p><strong>Methods: </strong>A descriptive, cross-sectional bicenter study was conducted among kidney transplant patients receiving outpatient care at two specialized medical centers in Algeria: the Urology Department of the Hospital Establishment for Urology, Nephrology, and Renal Transplantation in Constantine, and the Nephrology and Renal Transplantation Department of the University Hospital Center (CHU) in Blida, spanning from January to December 2022. Therapeutic adherence was assessed using the 8-item Morisky questionnaire, while the level of knowledge was analyzed through a 12-item questionnaire. Logistic regression was used to identify factors associated with non-adherence to therapy.</p><p><strong>Results: </strong>This study included 130 patients with an average age of 47 years and a sex ratio of 1.7. The results revealed therapeutic non-adherence in 40.8% of the patients. Multivariate analysis identified several potentially associated factors, including residence, unemployment status, lack of affiliation with a health insurance fund, the use of a therapeutic regimen involving triple therapy, the occurrence of adverse effects, limited education level, and insufficient disease knowledge. Furthermore, non-adherence was associated with an increased risk of graft rejection.</p><p><strong>Conclusion: </strong>The findings of this study highlight concerning therapeutic adherence among kidney transplant recipients, emphasizing the crucial importance of therapeutic education to improve treatment adherence and underscoring the need to integrate these factors into clinical patient management.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 2","pages":"95-111"},"PeriodicalIF":0.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving pre-emptive access to the kidney transplant waiting list between 2017 and 2021: assessment of a regional program in Aquitaine 在 2017 年至 2021 年间改善肾移植候选名单的抢先访问:对阿基坦大区计划的评估。
Pub Date : 2024-05-15 DOI: 10.1684/ndt.2024.64
Mathilde Prezelin-Reydit, Karine Moreau, Frederic Jambon, Eric Alezra, Grégoire Robert, Jean-Christophe Bernhard, Savva Assatourian, Cécile Degryse, Noëlle Boulonne, Arlette Communier, Brigitte Bonpunt, Benjamin Daviller, Olivier Delorme, Xabina Larre, Hannah Kaminski, Karen Leffondré, Pierre Merville, Lionel Couzi

Introduction: Pre-emptive access to the kidney transplant (KT) waiting list remains limited in France, with only 3.9% of patients on pre-emptive KT and 5.6% of patients registered at the time of initiation of dialysis. A similar trend was observed in Aquitaine. The aim of this study was to assess the impact of a regional program in terms of access to the waiting list for patients initiating a kidney replacement therapy (KRT).

Methods: We included all patients assessed for registration on the list between 2017 and 2020, 2017 being the reference year and 2018 the beginning of the program. Using the CRISTAL and REIN registries, we assessed changes in the number of patients on the list at the time of initiation of dialysis or transplantation.

Results: The number of new assessed candidates increased gradually each year from 255 in 2017 to 352 in 2020 (+38%). The number of patients on the list sharply increased in 2018 from 229 in 2017 to 319 in 2018 (+39.3%) and then remained stable. At the initiation of KRT, the proportion of patients registered on the waiting list increased gradually from 7.1% in 2017 to 18.2% in 2020. The proportion of pre-emptive KT remained stable between 2017 and 2021 (around 7%) with a decrease in 2020 (4.6%). Approximately 60% of patients had a contraindication to transplantation throughout the study.

Conclusion: This study showed that a regional program aimed at providing better information to healthcare professionals and patients and encouraging rapid assessment of transplant candidates could increase the rate of pre-emptive registration on the KT waiting list for eligible patients over 4 years.

导言:在法国,肾移植(KT)候选名单中的先期肾移植患者仍然有限,只有 3.9% 的先期肾移植患者和 5.6% 的患者在开始透析时进行了登记。阿基坦大区也出现了类似的趋势。本研究旨在评估一项地区计划对肾脏替代治疗(KRT)患者进入候诊名单的影响:我们纳入了所有在2017年至2020年期间被评估登记的患者,其中2017年为基准年,2018年为该计划的起始年。通过 CRISTAL 和 REIN 登记,我们评估了开始透析或移植时名单上患者人数的变化:新评估的候选者人数每年逐渐增加,从2017年的255人增加到2020年的352人(+38%)。2018年,名单上的患者人数从2017年的229人急剧增加到2018年的319人(+39.3%),随后保持稳定。在启动 KRT 时,登记在候诊名单上的患者比例从 2017 年的 7.1%逐渐增加到 2020 年的 18.2%。2017 年至 2021 年期间,先期 KT 的比例保持稳定(约 7%),2020 年有所下降(4.6%)。在整个研究过程中,约60%的患者有移植禁忌症:这项研究表明,一项旨在为医护人员和患者提供更多信息并鼓励对移植候选者进行快速评估的地区性计划,可以在4年内提高符合条件的患者在KT候选名单上的优先登记率。
{"title":"Improving pre-emptive access to the kidney transplant waiting list between 2017 and 2021: assessment of a regional program in Aquitaine","authors":"Mathilde Prezelin-Reydit, Karine Moreau, Frederic Jambon, Eric Alezra, Grégoire Robert, Jean-Christophe Bernhard, Savva Assatourian, Cécile Degryse, Noëlle Boulonne, Arlette Communier, Brigitte Bonpunt, Benjamin Daviller, Olivier Delorme, Xabina Larre, Hannah Kaminski, Karen Leffondré, Pierre Merville, Lionel Couzi","doi":"10.1684/ndt.2024.64","DOIUrl":"10.1684/ndt.2024.64","url":null,"abstract":"<p><strong>Introduction: </strong>Pre-emptive access to the kidney transplant (KT) waiting list remains limited in France, with only 3.9% of patients on pre-emptive KT and 5.6% of patients registered at the time of initiation of dialysis. A similar trend was observed in Aquitaine. The aim of this study was to assess the impact of a regional program in terms of access to the waiting list for patients initiating a kidney replacement therapy (KRT).</p><p><strong>Methods: </strong>We included all patients assessed for registration on the list between 2017 and 2020, 2017 being the reference year and 2018 the beginning of the program. Using the CRISTAL and REIN registries, we assessed changes in the number of patients on the list at the time of initiation of dialysis or transplantation.</p><p><strong>Results: </strong>The number of new assessed candidates increased gradually each year from 255 in 2017 to 352 in 2020 (+38%). The number of patients on the list sharply increased in 2018 from 229 in 2017 to 319 in 2018 (+39.3%) and then remained stable. At the initiation of KRT, the proportion of patients registered on the waiting list increased gradually from 7.1% in 2017 to 18.2% in 2020. The proportion of pre-emptive KT remained stable between 2017 and 2021 (around 7%) with a decrease in 2020 (4.6%). Approximately 60% of patients had a contraindication to transplantation throughout the study.</p><p><strong>Conclusion: </strong>This study showed that a regional program aimed at providing better information to healthcare professionals and patients and encouraging rapid assessment of transplant candidates could increase the rate of pre-emptive registration on the KT waiting list for eligible patients over 4 years.</p>","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 2","pages":"112-121"},"PeriodicalIF":0.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140915887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nephrologie & therapeutique
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1